Prospect Bio is a synthetic biology company building biosensors capable of measuring chemicals and small molecules within living cells that is headquartered in Brisbane, California and was founded in 2013 by Cameron Strachan and Giles Ochs. The company claims on their TROVE biosensor library has more than 10^9 naturally sourced biosensors.
On November 15, 2016 Prospect Bio announced raising $2.8 million in seed funding from Viking Global Investors, Viaduct Ventures, Think + Ventures, StartX, Rising Tide, Pallasite Ventures, OS Fund, Illumina, GVA LaunchGurus Fund, and 500 Startups.
In October 2016 Prospect Bio announced they will begin working with Ginkgo Bioworks to develop biosensors for improving process used by Ginkgo Bioworks related to effectively screening prototypes and accelerating strain development. The head of Ginko Bioworks test platform, Ned Tedford, made the following statement about his company's collaboration with Prospect Bio:
The synergy between our foundry tools and Prospect’s biosensors means lower costs and faster development times across a range of our projects,” he said. “We’re thrilled to be working with Prospect Bio on new tools that will help us grow our capabilities even further.
Timeline
Funding rounds
People
Andrei M. Marinescu
Investor
Ben Wang
Advisor
Bill Tobin
Investor
Daniella Russo
Advisor
Giles Ochs
Founder
Nina Patrick
Employee
Robert Neivert
Investor
Robert Sidney Cox
Employee
Tom Urban
Advisor
Will Horvat
Employee
Further reading
Ginkgo Bioworks and Prospect Bio to Collaborate on Tools to Accelerate Biological Engineering
BusinessWire
Ginkgo Bioworks and Prospect Bio will Collaborate to Develop and Deploy Biosensors
Christine Stevenson